United States - English - NLM (National Library of Medicine)

gland pharma limited - lincomycin hydrochloride (unii: m6t05z2b68) (lincomycin - unii:bod072yw0f) - lincomycin injection is indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. because of the risk of cdad, as described in the boxed warning , before selecting lincomycin the physician should consider the nature of the infection and the suitability of other alternatives. indicated surgical procedures should be performed in conjunction with antibacterial therapy. lincomycin injection may be administered concomitantly with other antimicrobial agents when indicated. lincomycin injection is not indicated in the treatment of minor bacterial infections or viral infections. to reduce the development of drug-resistant bacteria and maintain the effectiveness of lincomycin injection and other antibacterial drugs, lincomycin injection should be used only to treat or prevent infections that are proven

United States - English - NLM (National Library of Medicine)

huvepharma, inc. - lincomycin hydrochloride (unii: m6t05z2b68) (lincomycin - unii:bod072yw0f) - lincomycin 0.4 g in 1 g - for oral use in swine and broiler chickens only not for use in layer and breeder chickens keep out of reach of children indications and usage: swine: lincomycin hydrochloride soluble powder is indicated for the treatment of swine dysentery (bloody scours). broiler chickens: lincomycin hydrochloride soluble powder is indicated for the control of necrotic enteritis caused by clostridium perfringens susceptible to lincomycin. for oral use in swine and broiler chickens only not for use in layer or breeder chickens keep out of reach of children indications and usage: swine: lincomycin hydrochloride soluble powder is indicated for the treatment of swine dysentery (bloody scours). broiler chickens: lincomycin hydrochloride soluble powder is indicated for the control of necrotic enteritis caused by clostridium perfringens susceptible to lincomycin. for oral use in swine and broiler chickens only not for use in layer and breeder chickens keep out of reach of children indications and usage: swine: li

United States - English - NLM (National Library of Medicine)

quo vademus - lincomycin hydrochloride (unii: m6t05z2b68) (lincomycin - unii:bod072yw0f) - lincomycin 0.4 g in 1 g - broiler chickens: directions for use indication: lincomycin hydrochloride soluble powder is indicated for the control of necrotic enteritis caused by clostridium perfringens susceptible to lincomycin. dosage: administer at a dose rate of 64 mg of lincomycin per gallon of drinking water. treatment period: start medication as soon as the diagnosis of necrotic enteritis is determined. the drug should be administered for 7 consecutive days. administration: this packet will medicate 3000 gallons of drinking water providing 64 mg/gallon. note: after water medication is discontinued, a recommended control program for necrotic enteritis consists of feeding lincomycin premix at 2 grams lincomycin per ton of complete feed. swine: directions for use indication: lincomycin hydrochloride soluble powder is indicated for the treatment of swine dysentery (bloody scours). dosage: administer at a dose rate of 250 mg of lincomycin per gallon of drinking water. in clinical studies, this dose rate provided an average of

United States - English - NLM (National Library of Medicine)

xgen pharmaceuticals djb, inc. - lincomycin hydrochloride (unii: m6t05z2b68) (lincomycin - unii:bod072yw0f) - lincomycin 300 mg in 1 ml - lincomycin injection, usp is indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. because of the risk of cdad, as described in the boxed warning , before selecting lincomycin the physician should consider the nature of the infection and the suitability of other alternatives. indicated surgical procedures should be performed in conjunction with antibacterial therapy. lincomycin injection may be administered concomitantly with other antimicrobial agents when indicated. lincomycin is not indicated in the treatment of minor bacterial infections or viral infections. to reduce the development of drug-resistant bacteria and maintain the effectiveness of lincomycin and other antibacterial drugs, lincomycin should be used only to treat or prevent infections that are proven or strongly suspected

United States - English - NLM (National Library of Medicine)

durvet, inc. - lincomycin hydrochloride (unii: m6t05z2b68) (lincomycin - unii:bod072yw0f) - lincomycin 300 mg in 1 ml - anada #200-315, approved by f.d.a. lincomycin injectable brand of lincomycin hydrochloride injectable for intramuscular use in swine over 300 lbs. only swine antibiotic lincomycin injectable contains lincomycin hydrochloride, an antibiotic produced by  sterptomyces lincolnensis var. lincolnensis, which is chemically distinct from all other clinically available antibiotics and is isolated as a white crystalline solid. indicated for the treatment of arthrits caused by susceptible organisms and for mycoplasma pneumonia. indications for swine lincomycin injectable is indicated for the treatment of infectious forms of arthritis caused by organisms sensitive to its activity. this includes most of the organisms responsible for the various infectious arthritides in swine, such as staphylococci, streptococci, erysipelothrix and mycoplasma spp. it is also indicated for the treatment of mycoplasma pneumonia. as with all drugs, the use of lincomycin injectable is contraindicated in animals previously found to be hyper

Australia - English - Department of Health (Therapeutic Goods Administration)

southern xp ip pty ltd - lincomycin hydrochloride monohydrate, quantity: 680.4 mg (equivalent: lincomycin, qty 600 mg) - injection, solution - excipient ingredients: benzyl alcohol; water for injections - lincomycin sxp is indicated in the treatment of serious infections due to susceptible strains of gram-positive aerobes such as streptococci, pneumococci and staphylococci.,its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgement of the physician, a penicillin is inappropriate. because of the risk of colitis (see precautions), before selecting lincomycin the physician should consider the nature of infection and the suitability of less toxic alternatives (e.g. erythromycin).,lincomycin injection has been demonstrated to be effective in the treatment of staphylococcal infections resistant to other antibiotics and susceptible to lincomycin. staphylococcal strains resistant to lincomycin injection have been recovered; culture and susceptibility studies should be done in conjunction with lincomycin injection therapy. in the case of macrolides, partial but not complete cross resistance may occur. the drug may be administered concomitantly with other antimicrobial agents with which it is compatible when indicated (see precautions).,the specific infections for which lincomycin sxp is indicated are as follows:,upper respiratory infections including tonsillitis, pharyngitis, otitis media, sinusitis, scarlet fever and as adjuvant therapy for diphtheria. effectiveness in the treatment of mastoiditis would be anticipated.,lower respiratory infections including acute and chronic bronchitis and pneumonia.,skin and skin structure infections including cellulitis, furuncles, abscesses, impetigo, acne and wound infections. conditions such as erysipelas, lymphadenitis, paronychia (panaritium), mastitis and cutaneous gangrene should, if caused by susceptible organisms, respond to lincomycin therapy.,bone and joint infections including osteomyelitis and septic arthritis.,septicaemia and endocarditis. selected cases of septicaemia and/or endocarditis due to susceptible organisms have responded well to lincomycin. however, bactericidal drugs are often preferred for these infections.,bacillary dysentery. although shigella is resistant to lincomycin in vitro (mic approximately 200-400 micrograms/ml), lincomycin has been effective in its treatment due to the very high levels of lincomycin attained in the bowel (approximately 3000-7000 micrograms/gram of stool).

Australia - English - Department of Health (Therapeutic Goods Administration)

southern xp ip pty ltd - lincomycin hydrochloride monohydrate, quantity: 340.2 mg (equivalent: lincomycin, qty 300 mg) - injection, solution - excipient ingredients: benzyl alcohol; water for injections - lincomycin sxp is indicated in the treatment of serious infections due to susceptible strains of gram-positive aerobes such as streptococci, pneumococci and staphylococci.,its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgement of the physician, a penicillin is inappropriate. because of the risk of colitis (see precautions), before selecting lincomycin the physician should consider the nature of infection and the suitability of less toxic alternatives (e.g. erythromycin).,lincomycin injection has been demonstrated to be effective in the treatment of staphylococcal infections resistant to other antibiotics and susceptible to lincomycin. staphylococcal strains resistant to lincomycin injection have been recovered; culture and susceptibility studies should be done in conjunction with lincomycin injection therapy. in the case of macrolides, partial but not complete cross resistance may occur. the drug may be administered concomitantly with other antimicrobial agents with which it is compatible when indicated (see precautions).,the specific infections for which lincomycin sxp is indicated are as follows:,upper respiratory infections including tonsillitis, pharyngitis, otitis media, sinusitis, scarlet fever and as adjuvant therapy for diphtheria. effectiveness in the treatment of mastoiditis would be anticipated.,lower respiratory infections including acute and chronic bronchitis and pneumonia.,skin and skin structure infections including cellulitis, furuncles, abscesses, impetigo, acne and wound infections. conditions such as erysipelas, lymphadenitis, paronychia (panaritium), mastitis and cutaneous gangrene should, if caused by susceptible organisms, respond to lincomycin therapy.,bone and joint infections including osteomyelitis and septic arthritis.,septicaemia and endocarditis. selected cases of septicaemia and/or endocarditis due to susceptible organisms have responded well to lincomycin. however, bactericidal drugs are often preferred for these infections.,bacillary dysentery. although shigella is resistant to lincomycin in vitro (mic approximately 200-400 micrograms/ml), lincomycin has been effective in its treatment due to the very high levels of lincomycin attained in the bowel (approximately 3000-7000 micrograms/gram of stool).

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

zoetis australia pty ltd - lincomycin as lincomycin hydrochloride - unknown - lincomycin as lincomycin hydrochloride antibiotic active 0.0 - active constituent

United States - English - NLM (National Library of Medicine)

mwi veterinary supply, inc. - lincomycin hydrochloride (unii: m6t05z2b68) (lincomycin - unii:bod072yw0f) - indicated for the treatment of arthritis caused by susceptible organisms and for mycoplasma pneumonia. lincomycin injectable is indicated for the treatment of infectious forms of arthritis caused by organisms sensitive to its activity. this includes most of the organisms responsible for the various infectious arthritides in swine, such as staphylococci, streptococci, erysipelothrix and mycoplasma spp .  it is also indicated for the treatment of mycoplasma pneumonia. as with all drugs, the use of lincomycin injectable is contraindicated in animals previously found to be hypersensitive to the drug.

United States - English - NLM (National Library of Medicine)

pharmacia & upjohn company llc - lincomycin hydrochloride (unii: m6t05z2b68) (lincomycin - unii:bod072yw0f) - lincomycin 300 mg in 1 ml - lincocin is indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. because of the risk of cdad, as described in the boxed warning , before selecting lincomycin the physician should consider the nature of the infection and the suitability of other alternatives. indicated surgical procedures should be performed in conjunction with antibacterial therapy. lincocin may be administered concomitantly with other antimicrobial agents when indicated. lincocin is not indicated in the treatment of minor bacterial infections or viral infections. to reduce the development of drug-resistant bacteria and maintain the effectiveness of lincocin and other antibacterial drugs, lincocin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.